大鼠脑小病灶增强与钆沉积:gadopiclenol与钆贝葡胺对比
研究在大鼠模型上比较gadopiclenol与钆贝葡胺:在相同剂量下,gadopiclenol对脑小病灶的强化体素数约高2倍;重复静脉注射后,gadopiclenol在深部小脑核团未见T1高信号,中枢神经系统和肌肉钆浓度较钆贝葡胺低2至3倍。
要点
- 相同剂量下gadopiclenol对脑小病灶的强化体素数约为钆贝葡胺的2倍。
- 重复注射后钆贝葡胺组深部小脑核团出现T1高信号,gadopiclenol组未见。
- gadopiclenol组中枢神经系统和肌肉钆浓度较钆贝葡胺低2至3倍。
核心结论
- 在脑小病灶大鼠模型中,相同剂量gadopiclenol的病灶强化体素数约为钆贝葡胺的2倍。
- 重复静脉注射后,gadopiclenol在深部小脑核团不引起T1高信号,钆沉积较钆贝葡胺少。
研究设计与样本
- 研究一:脑小病灶大鼠模型,2.35 T MRI,gadopiclenol与钆贝葡胺按0.1 mmol/kg体重交替交叉注射,间隔4.4±1.0小时(范围3.5-6.1小时),n=6。
- 研究二:健康大鼠,4.7 T MRI,单次静脉注射1.2 mmol/kg体重后23分钟内评估第四脑室T1强化,每组n=6。
- 研究三:健康大鼠,5周内静脉注射20次0.6 mmol/kg体重gadopiclenol或钆贝葡胺或等体积生理盐水,每组n=10;末次注射后1个月用ICP-MS测钆浓度。
关键影像表现/征象
- 脑小病灶模型中,gadopiclenol组病灶强化体素数较钆贝葡胺组高约2倍。
- 单次静脉注射后数分钟内,两组均可见第四脑室T1强化。
- 重复给药期间,gadopiclenol组出现第四脑室一过性强化。
- 末次注射后1个月内,钆贝葡胺组深部小脑核团出现T1高信号,gadopiclenol组未见。
诊断标准与关键数值
- 脑小病灶强化程度以强化体素数评估,gadopiclenol组约为钆贝葡胺组的2倍(0.1 mmol/kg体重,2.35 T)。
- 钆沉积以深部小脑核团T1强化和ICP-MS测钆浓度评估;gadopiclenol组中枢神经系统和肌肉钆浓度较钆贝葡胺组低2至3倍。
临床应用与阅片要点
- 在相同剂量下,gadopiclenol可能提高脑小病灶的检出敏感性,阅片时注意强化体素数差异。
- 使用钆贝葡胺后随访MRI若见深部小脑核团T1高信号,应想到钆沉积可能。
- gadopiclenol的大环结构可能减少深部小脑核团T1高信号,但需结合临床和序列参数判断。
局限性
- 研究仅在大鼠模型中进行,结果不能直接外推到人类。
- 样本量小(n=6或10),统计效能有限。
- 研究一交叉设计间隔较短(4.4±1.0小时),可能存在残留对比剂影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of the set of studies was to compare gadopiclenol, a new high relaxivity gadolinium (Gd)-based contrast agent (GBCA) to gadobenate dimeglumine in terms of small brain lesion enhancement and Gd retention, including T1 enhancement in the cerebellum.
MATERIALS AND METHODS: In a first study, T1 enhancement at 0.1 mmol/kg body weight (bw) of gadopiclenol or gadobenate dimeglumine was evaluated in a small brain lesions rat model at 2.35 T. The 2 GBCAs were injected in an alternated and cross-over manner separated by an interval of 4.4 ± 1.0 hours (minimum, 3.5 hours; maximum, 6.1 hours; n = 6). In a second study, the passage of the GBCAs into cerebrospinal fluid (CSF) was evaluated by measuring the fourth ventricle T1 enhancement in healthy rats at 4.7 T over 23 minutes after a single intravenous (IV) injection of 1.2 mmol/kg bw of gadopiclenol or gadobenate dimeglumine (n = 6/group). In a third study, Gd retention at 1 month was evaluated in healthy rats who had received 20 IV injections of 1 of the 2 GBCAs (0.6 mmol/kg bw) or a similar volume of saline (n = 10/group) over 5 weeks. T1 enhancement of the deep cerebellar nuclei (DCN) was assessed by T1-weighted magnetic resonance imaging at 2.35 T, performed before the injection and thereafter once a week up to 1 month after the last injection. Elemental Gd levels in central nervous system structures, in muscle and in plasma were determined by inductively coupled plasma mass spectrometry (ICP-MS) 1 month after the last injection.
RESULTS: The first study in a small brain lesion rat model showed a ≈2-fold higher number of enhanced voxels in lesions with gadopiclenol compared with gadobenate dimeglumine. T1 enhancement of the fourth ventricle was observed in the first minutes after a single IV injection of gadopiclenol or gadobenate dimeglumine (study 2), resulting, in the case of gadopiclenol, in transient enhancement during the injection period of the repeated administrations study (study 3). In terms of Gd retention, T1 enhancement of the DCN was noted in the gadobenate dimeglumine group during the month after the injection period. No such enhancement of the DCN was observed in the gadopiclenol group. Gadolinium concentrations 1 month after the injection period in the gadopiclenol group were slightly increased in plasma and lower by a factor of 2 to 3 in the CNS structures and muscles, compared with gadobenate dimeglumine.
CONCLUSIONS: In the small brain lesion rat model, gadopiclenol provides significantly higher enhancement of brain lesions compared with gadobentate dimeglumine at the same dose. After repeated IV injections, as expected for a macrocyclic GBCA, Gd retention is minimalized in the case of gadopiclenol compared with gadobenate dimeglumine, resulting in no T1 hypersignal in the DCN.
引用
- Violas X, Rasschaert M, Santus R, et al. Small Brain Lesion Enhancement and Gadolinium Deposition in the Rat Brain: Comparison Between Gadopiclenol and Gadobenate Dimeglumine. Invest Radiol. 2022. PMID: 34411032. doi:10.1097/RLI.0000000000000819
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。